| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
70,010,000 |
| Market
Cap: |
646.89(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$6.18 - $12.9 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Zymeworks is a clinical-stage biopharmaceutical company focused on the development of multifunctional biotherapeutics. Co.'s primary product candidate, zanidatamab, is a bispecific (dual-targeting) antibody that targets two domains of the human epidermal growth factor receptor 2. Co.'s second product candidate, ZW49, combines the design of zanidatamab with its ZymeLink antibody-drug conjugate platform, comprised of its proprietary cytotoxin (cancer cell-killing compound) and cleavable linker. Co. is also developing a pipeline of preclinical product candidates and discovery-stage programs in oncology (including immuno-oncology agents) and other therapeutic areas.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
2,475 |
| Total Sell Value |
$0 |
$0 |
$0 |
$20,045 |
| Total People Sold |
0 |
0 |
0 |
1 |
| Total Sell Transactions |
0 |
0 |
0 |
1 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Poon David Kai Yuen |
See Remarks |
• – – |
2019-05-06 |
4 |
OE |
$3.53 |
$2,824 |
D/D |
800 |
800 |
|
- |
|
| Tehrani Ali |
Chief Executive Officer |
• • – |
2019-03-29 |
4 |
S |
$16.24 |
$48,720 |
I/I |
(3,000) |
59,286 |
|
- |
|
| Lilly Eli & Co |
10% Owner |
– – • |
2019-01-31 |
4 |
S |
$16.00 |
$4,000,000 |
D/D |
(250,000) |
2,898,647 |
|
- |
|
| Klompas Neil A |
Chief Financial Officer |
• – – |
2019-01-08 |
4 |
A |
$12.48 |
$5,167 |
D/D |
414 |
1,201 |
|
- |
|
| Hausman Diane |
Chief Medical Officer |
• – – |
2019-01-08 |
4 |
A |
$12.48 |
$6,228 |
D/D |
499 |
2,499 |
|
- |
|
| Lilly Eli & Co |
10% Owner |
– – • |
2018-11-06 |
4 |
S |
$14.00 |
$9,800,000 |
D/D |
(700,000) |
3,148,647 |
|
- |
|
| Lilly Eli & Co |
10% Owner |
– – • |
2018-09-24 |
4 |
S |
$16.36 |
$33,162 |
D/D |
(2,027) |
3,848,647 |
|
- |
|
| Lilly Eli & Co |
10% Owner |
– – • |
2018-09-18 |
4 |
S |
$14.56 |
$100,027 |
D/D |
(6,870) |
3,850,674 |
|
- |
|
| Lilly Eli & Co |
10% Owner |
– – • |
2018-09-17 |
4 |
S |
$14.58 |
$100,092 |
D/D |
(6,865) |
3,857,544 |
|
- |
|
| Lilly Eli & Co |
10% Owner |
– – • |
2018-09-14 |
4 |
S |
$14.58 |
$131,351 |
D/D |
(9,009) |
3,864,409 |
|
- |
|
| Lilly Eli & Co |
10% Owner |
– – • |
2018-09-13 |
4 |
S |
$14.32 |
$299,288 |
D/D |
(20,900) |
3,873,418 |
|
- |
|
| Lilly Eli & Co |
10% Owner |
– – • |
2018-09-12 |
4 |
S |
$14.83 |
$149,175 |
D/D |
(10,059) |
3,894,318 |
|
- |
|
| Lilly Eli & Co |
10% Owner |
– – • |
2018-09-11 |
4 |
S |
$14.87 |
$167,689 |
D/D |
(11,277) |
3,904,377 |
|
- |
|
| Lilly Eli & Co |
10% Owner |
– – • |
2018-09-10 |
4 |
S |
$14.44 |
$64,980 |
D/D |
(4,500) |
3,915,654 |
|
- |
|
| Lilly Eli & Co |
10% Owner |
– – • |
2018-08-31 |
4 |
S |
$14.26 |
$9,982 |
D/D |
(700) |
3,920,154 |
|
- |
|
| Lilly Eli & Co |
10% Owner |
– – • |
2018-08-30 |
4 |
S |
$14.35 |
$49,364 |
D/D |
(3,440) |
3,920,854 |
|
- |
|
| Lilly Eli & Co |
10% Owner |
– – • |
2018-08-29 |
4 |
S |
$14.26 |
$32,969 |
D/D |
(2,312) |
3,924,294 |
|
- |
|
| Lilly Eli & Co |
10% Owner |
– – • |
2018-08-14 |
4 |
S |
$14.28 |
$42,840 |
D/D |
(3,000) |
3,926,606 |
|
- |
|
| Lilly Eli & Co |
10% Owner |
– – • |
2018-08-13 |
4 |
S |
$14.33 |
$64,929 |
D/D |
(4,531) |
3,929,606 |
|
- |
|
| Lilly Eli & Co |
10% Owner |
– – • |
2018-08-10 |
4 |
S |
$14.28 |
$27,103 |
D/D |
(1,898) |
3,934,137 |
|
- |
|
| Lilly Eli & Co |
10% Owner |
– – • |
2018-08-03 |
4 |
S |
$13.55 |
$22,358 |
D/D |
(1,650) |
3,936,035 |
|
- |
|
| Lilly Eli & Co |
10% Owner |
– – • |
2018-08-02 |
4 |
S |
$13.31 |
$258,214 |
D/D |
(19,400) |
3,937,685 |
|
- |
|
97 Records found
|
|
Page 4 of 4 |
|
|
0.43 (4.88%) 
